Objective To compare a new loading dose regimen for intravenous ritodrine administration in preterm labour with the conventional dose regimen.
INTRODUCTION
Classically, ritodrine, the most commonly used betamimetic agent for treatment of preterm labour, is administered intravenously in stepwise incre mental doses until uterine quiescence is achieved or side effects preclude further increases1,2. This approach results in a gradual increase in plasma ritodrine concentrations that continues even after has r c i '1 * Bee total dose and dose changes'-, r ' we designed a loading dose schedule with two main characteristics". It avoids doses in excess of those needed to achieve and maintain uterine quiescence ind r only one or two adjustments of the infusion rate to reach an effective minimal infusion rate".
We now report on a randomised study in which the new loading dose regimen was compared with the conventional system of rito-drine administration for treatment of preterm labour.
METHODS

Five teaching hospitals participated in this 4 year
(shorter at some hospitals) after ethical approval of a protocol that consisted of two parts. The first part, which is reported here, consisted of a comparison between loading dose (LD) and a conventional incremental dose (ID) regimen for intravenous ritodrine administration ln labour. The ; part. which is reported separately, was a double-blind, placebo-controlled evaluation of sustained release ritodrine capsules for maintaining uterine relax ation in those women whose preterm labour had been arrested by these treatments (Fig. I) 7 . Irrespective of whether they had received the LD or the ID schedule, women participating in the second par t had an equal chance of being allocated blindly to placebo or sustained release ritodrine capsules. This implies that the influence of main- tenance treatment (active or placebo) on neonatal outcome will be unbiased and similar for both the LD and ID schedules (Fig. 1) . A consecutive series of 203 healthy women in preterm labour, requiring tocolysis with betamimetics because of three or more regular con tractions per 15 min and/or an increase in cervical 50 |ig/min for 12-24 h whereupon oral maindilatation before 34 weeks of gestation, partici-tenance treatment was started. The latter consisted pated in this study. After informed consent, of either placebo or sustained release capsules of women were allocated at random by numbered, ritodrine (240 mg daily), in a double-blind fashion, opaque, sealed envelopes to either one of two for seven days7. treatment groups. Two additional envelopes were Treatment, whether intravenous or oral, was drawn erroneously for women who failed to meet stopped in the event of severe side effects, signs of the entry criterion of labour before 34 weeks and intrauterine infection or fetal distress, and imseven for women who had exclusion criteria, such minent delivery. The use of other tocolytic drugs as earlier tocolytic treatment in the current was not allowed unless clinically indicated because pregnancy (n = 4) or a diagnosis of intrauterine of failure to respond to ritodrine treatment alone, infection (n -1), fetal anomaly (n = 1), or full All other concurrent medication was restricted dilatation (« = 1) before randomisation. These with the exception of corticosteroid administration nine women were considered as nonparticipants for fetal lung maturation which was recommended. prior to any assessment of outcomes.
Recruitment was stopped when the predeter
The main outcome parameter was successful tocolysis defined as the end of intravenous treatmined sample size of 200 women was known to ment in the absence of progressive labour or have been achieved at the five centres. This sample achievement of 34 weeks of gestation, whichever size has an 80% power of detecting a 20% occurred first. Additional predefined outcomes difference in the frequency of successful tocolysis were: the total dose of ritodrine administered, the between the two treatment groups; (a 0-05).
duration of intravenous treatment until tapering Women allocated to the experimental arm (LD; off, infusion rates of ritodrine 12, 24 and 48 h after 101) received a loading dose of 200 |j,g/min start of treatment, and the number of dose ritodrine until tocolysis was reached whereupon adjustments in the first 12, 24 and 48 h of n the infusion rate was reduced in a standard fashion calculated from the interval between start of the treatment and tocolysis (Table   treatment. Assessments of safety and tolerance were made The convenon the basis of adverse events, dose adaptations tional (ID; n = 102) treatment consisted of a dose prompted by side effects, and changes in fetal of 50 ng/min ritodrine that was increased with heart rate, maternal heart rate and blood pressure 50 |4,g/min about every 15 min until uterine quiesc-between the start of the infusion and the first few ence was reached or until side effects prohibited hours of treatment. Plasma concentrations of further dose increases. Both treatments were sodium, potassium, chloride and bicarbonate were administered with an infusion pump. After cess-measured at the start of treatment and 8 to 16 and ation of uterine contractions, treatment was 24 to 40 h afterwards. continued for 24 to 48 h in both groups. Thereafter, Before analysis, all data entry sheets were the dose was reduced to a maintenance level of assessed by one of us (M.J.N.C.K.), blinded to RCOG 1996 Br J Obstet Gynaecol 103, 695-701 treatment allocation and neonatal outcome. Statofficially prescribed. We accepted this as normal istical analysis was performed in the SAS analysis variation within the confines of clinical practice. system using Student's t test, Wilcoxon two sample test and the %2 or Cochran-Mantel-Haenszel x2
Successful tocolysis was defined as arrest of intravenous treatment in the absence of progressive tests. The CIA program was used for confidence labour or at reaching a gestational age of 34 interval analysis RESULTS 8 weeks. Tocolysis was considered to be only partially successful if another agent (always indomethacin) had been co-administered at some stage. In the five participating centres 212 envelopes were
The incidence of successful tocolysis, partial drawn for the 203 participants and nine nonsuccess and failure were similar in both groups participants. Two women were excluded from the (Table 3 ). In eight women treatment was stopped analysis : one in the LD group because of lost case because of suspected intrauterine records and one in the ID group because she was (n 4), abruption (n -2) or fetal distress (n 2 ), erroneously started on the loading dose and was rendering an assessment in terms of successful or 5 k * therefore withdrawn from the study by her failed tocolysis meaningless (not obstetrician. Both women gave birth to live infants Table 3 ). who survived.
The total amount of ritodrine used up to the The overall evaluation was performed on the start of tapering off did not differ between groups data of the remaining 201 women of whom 100 had (Table 3) . Also the mean infusion rates in jig/min been allocated to the experimental (LD) schedule at 12, 24 and 48 h after start of treatment were and 101 to the conventional (ID) schedule. The similar as was the duration of intravenous treatgroups did not differ statistically in terms of age, ment until the start of maintenance (Table 3) . gestational age, number of twins and triplets, Statistically there was a highly significant diffBishop score9, tocolytic index10, and incidence of erence in the number of dose adjustments in the ruptured membranes (Table 2 ). There were 95 first 12, 24 and 48 h of treatment (Cochranwomen (47 %; 50 from the LD group and 45 from Mantel-Haenszel, P< 0-001; Table 3 ). Side the ID group; n.s.) who subsequently participated effects (Table 4) precluding further dose increments in the double-blind maintenance trial (Fig. 1) .
or prompting a lowering or even arrest of the The loading dose schedule was always admiinfusion occurred significantly more often in the nistered according to protocol (Table 1) , but the ID group (Cochran-Mantel-Haenszel, P incremental dose schedule was started with 100 p,g Table 3) .
per min in seven women and in only 30 % of the Starting with the relatively high loading dose women (n = 32) was the time interval for dose (200 |j.g/min) in the LD group caused augmentations strictly observed at 15 min ; in the complaints and side effects, than the low starting others the interval was longer at 20 (n 34) or dose of the incremental scheme (50 jig/min) which even 30 min (n = 30). This was because the had to be upgraded several times. In only one participating clinicians were used to being more woman in the ID group was the infusion stopped cautious with the conventional infusion scheme in the first 12 h because of severe effects often applying it in a more gradual way than (headache, dizziness, palpitations, tremor, dysp- noea, tachycardia, nausea and agitation) ; she gave birth within 4 h of stopping treatment. In 22 other women (LD : 7 ; ID : 15) the infusion rate could not be increased or had to be lowered because of side effects (Table 3) . Changes in serum electrolytes and bicarbonate before and 8 to 16 and 24 to 40 h after the start of treatment did not differ between the groups. The largest change was seen in potassium levels which decreased significantly (P < 0*001) from before treatment in the entire group. Changes in chloride, sodium and bicarbonate were not remarkable.
Maternal heart rate and blood pressure were recorded more frequently in the ID group than in the LD group, because such measurements were often linked to adjustments in the infusion rate which were more frequent in the ID group. There were no statistically significant differences between the LD and ID group in maternal heart rate, increasing, respectively, by 30 and 27 beats per min, and in fetal heart rate which increased by bilirubinaemia tended to be more frequent in the 14beats/min in both groups. Changes in or ID group than in the LD group (Table 5 ). absolute levels of systolic blood pressures were not statistically different between both trial arms. The DISCUSSION proportion of women with a drop in diastolic As betamimetic agents are potent drugs that can blood pressure was significantly greater in the ID cause severe adverse effects, it is important to limit group (LD: 49%; ID: 73 %), but the extent of the the dose and duration of treatment to what is decrease was similar for both groups. Changes in thought to be clinically useful11. From our previous pulse pressure in both groups were comparable work we had anticipated that the LD schedule would result in lower infusion rates and a smaller and of negligible clinical importance.
«
The proportions of women delivering before 32, total amount of ritodrine than the conventional 34 and 37 weeks were similar in both treatment ID schedule recommended by the manufacturer, groups (Table 3) . Including 17 twin and 2 triplet While it is disappointing that this did not pregnancies each treatment group contains 111 materialize, there is an explanation for it. Being infants with mean birthweights of 2421+784 g in aware of the potential hazards of ritodrine adthe LD group and 2570 +879 g in the ID group. ministration and the fact that side effects are There was one unexplained intrauterine death at associated nearly as much with changes in infusion term in the LD group eight weeks after stopping rates as with the rates themselves, clinicians had ritodrine treatment. Four neonatal deaths ocbecome more cautious in their application of the curred in the ID group (Table 5) ; two of these conventional infusion schedule4,5. This was shown were due to immaturity in a twin pregnancy (25 by the fact that clinicians tended to observe longer between dose increments than the ID weeks), one to cord prolapse and one to hydroThere were no maternal deaths and no protocol prescribed. While increasing experience instances of pulmonary oedema.
with the new loading dose regimen may have The main neonatal morbidity was respiratory accentuated this tendency, data were not analysed distress syndrome which occurred with equal before completion of the trial and there was no frequency in both treatment groups ( Table 5 ).
evidence that the incremental regimen was applied Periventricular-intraventricular haemorrhage was less conscientiously at the end than at the beginning less frequent in the LD group (n -4) than in the of the trial. ID groups (n =15; Table 5 ), but a difference in Despite the more cautious approach in applying this outcome was not a prior hypothesis of our the conventional regimen, the loading dose schedoutcomes except adule was still tolerated better, particularly during study. All mission to neonatal care and hyperthe t md most crucial first 12 h of treatment.
On the whole, the incidence of all side effects was incidence20. This does not necessarily exclude, greater with the ID than with the LD schedule, but though, that our present findings represent a true the difference was less pronounced than we had instead of a chance difference between the two anticipated. We should point out that clinicians treatment regimens. If this were so, it would and pregnant women were not blinded to the constitute a major advantage for the loading dose treatment schedule and that only the analysis of regimen. data, but not their registration, occurred without knowledge of the treatment group.
As the loading dose scheme is at least equally effective as the incremental dose schedule while As anticipated, tocolysis was reached with far needing fewer dose adjustments and being better fewer dose adjustments when using the LD rather tolerated in practice, we recommend the loading than the ID schedule. This may have a beneficial dose schedule as the preferred and safest of the effect in that each dose adjustment carries a risk of two approaches to tocolytic treatment with ritoerror. This is particularly important when the drine in preterm labour. adjustment calls for an increase in infusion rate and when the clinical staff have relatively experience with the use of this powerful agent.
haemorrhage in preterm infants18'18, others have reported a more than twofold increase in the incidence of periventricular-intraventricular haemorrhage in infants whose mothers had been treated with betamimetics12. The best data avail able originate from the randomised controlled trials of betamimetic treatment19,20. These do not indicate an increased risk of periventricularintraventricular haemorrhage and the results of the largest trial are more likely to be compatible with a decrease rather than an increase in its RCOG 1996 Br J Obstet Gvnaecol 103, 695-701
